A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Clinical trial NCT05241093 · UNKNOWN
Trial details
- NCT number
- NCT05241093
- Sponsor
- Tarapeutics Science Inc.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-29
- Primary completion
- 2025-12-30
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.